Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.34 |
| ▸ | MAOB | P27338 | 4/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | USP14 | P54578 | 1/20 | 0.31 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL925379 | 0.73 | IDO1 (0.56) | MAOAMAOB | |
| SCHEMBL5424014 | 0.72 | DDB1 (0.37) | MAOAMAOBATMDDB1CRBN | |
| Bromide SCHEMBL17100513 | 0.72 | IDO1 (0.35) | USP14 | |
| SCHEMBL5277836 | 0.72 | ATM (0.35) | ATMLNPEP | |
| SCHEMBL5213250 | 0.71 | MAOA (0.42) | MAOAMAOBATMDDB1CRBN | |
| SCHEMBL925026 | 0.71 | DDB1 (0.52) | MAOAMAOBATMDDB1CRBN | |
| SCHEMBL11942311 | 0.71 | IDO1 (0.38) | — | |
| SCHEMBL840465 | 0.71 | GABRA1 (0.45) | — | |
| SCHEMBL2566058 | 0.71 | PRMT6 (0.44) | MAOAMAOBATMDDB1CRBN | |
| SCHEMBL501378 | 0.70 | MRGPRX4 (0.41) | MAOBUSP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE44874-E1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2014-04-29 | — | — | US | disclosed |
| EP-2042168-B1 | Inhalation formulation comprising phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LTD (GB) | 2013-10-23 | — | — | EP | disclosed |
| US-8198483-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2012-06-12 | — | — | US | disclosed |
| US-20110269970-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| US-7982067-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2011-07-19 | — | — | US | disclosed |
| US-20110009631-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | GLAXO GROUP LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| US-7776895-B2 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2010-08-17 | — | — | US | disclosed |
| EP-2042168-A1 | Inhalation device comprising phenethanolamine derivatives for treatment of respiratory diseases | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| US-20090068273-A1 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| EP-1425001-B1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| US-7439393-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2008-10-21 | — | — | US | disclosed |
| US-7361787-B2 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2008-04-22 | — | — | US | disclosed |
| US-20080003290-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | GLAXO GROUP LIMITED (GB) | 2008-01-03 | — | — | US | disclosed |
| US-20050075394-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | US | disclosed |
| EP-1425001-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003024439-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080003290-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | PHOSPHO1, PNMT, PEBP1 | MAOA 335/4885MAOB 557/4885ATM 3245/4885 |
| US-20110269970-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | PNMT, HRH2, CHKB | MAOA 654/4885MAOB 853/4885ATM 4325/4885 |
| US-20110009631-A1 | Phenethanolamine Derivatives for Treatment of Respiratory Diseases | PHOSPHO1, PNMT, PEBP1 | MAOA 410/4885MAOB 406/4885ATM 2743/4885 |
| US-20050075394-A1 | Phenethanolamine derivatives for treatment of respiratory diseases | PHOSPHO1, PNMT, PEBP1 | MAOA 280/4885MAOB 455/4885ATM 3073/4885 |
| US-20090068273-A1 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases | PNMT, CHRM3, HRH4 | MAOA 724/4885MAOB 972/4885ATM 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.